138 related articles for article (PubMed ID: 36804443)
1. IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
Scovell JM; Stovsky M; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Klein EA
Urology; 2023 May; 175():132-136. PubMed ID: 36804443
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study.
Klein EA; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Stovsky M
Urol Oncol; 2022 Sep; 40(9):408.e9-408.e18. PubMed ID: 35840465
[TBL] [Abstract][Full Text] [Related]
3. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
4. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
[TBL] [Abstract][Full Text] [Related]
5. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
6. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
10. Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.
Benidir T; Hofmann M; Lone Z; Nguyen JK; Purysko AS; Stovsky M; Klein EA; Weight CJ
Urology; 2022 Oct; 168():150-155. PubMed ID: 35680047
[TBL] [Abstract][Full Text] [Related]
11. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
12. IsoPSA
Scovell JM; Hettel D; Abouassaly R; Almassi N; Berglund R; Breaux T; Weight C; Isac W; Zampini A; Stark E; Rochelle R; Kestranek A; Stovsky M; Klein EA
Urol Pract; 2022 Mar; 9(2):173-180. PubMed ID: 37145695
[TBL] [Abstract][Full Text] [Related]
13. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
Robinson D; Garmo H; Holmberg L; Stattin P
Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
[TBL] [Abstract][Full Text] [Related]
14. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
15. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
17. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
20. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]